What CGM sensor drift actually is — and what causes it
CGM sensor drift is a progressive, systematic change in an electrochemical sensor’s sensitivity to glucose over time — distinct from random noise — that causes the device to over-report or under-report glucose values as its signal baseline or gain shifts. The accuracy of CGM readings degrades because of four major interacting factors: physiology, sensor calibration, noise, and engineering, as established in foundational work by King and Abbott (2007). Each factor is mechanistically independent, but all compound in the final glucose reading.
At the electrochemical level, an amperometric glucose sensor’s sensitivity depends on three physical systems that all evolve during wear: the enzymatic activity of the glucose oxidase layer, the permeability of the outer diffusion-limiting membranes, and the tissue response at the insertion site. As glucose oxidase degrades, fewer enzymatic reactions occur per unit of glucose present, so the current output falls — the sensor reads low. As membranes swell or foul, the diffusion kinetics change, altering the relationship between interstitial glucose concentration and measured current. As the body responds to the foreign body at the insertion site, local biochemistry further modifies the signal environment.
CGM sensor drift refers to a progressive change in electrochemical sensitivity to glucose over time, manifesting as a systematic bias in readings caused by enzymatic degradation of the glucose oxidase layer, changes in outer membrane permeability, and tissue response at the insertion site — not random noise.
A physiological source of apparent drift that is often conflated with chemical degradation is the blood-to-interstitial glucose time lag. Because CGM sensors measure glucose in interstitial fluid (ISF) rather than blood, there is an inherent delay between a change in blood glucose and the corresponding change in ISF glucose. This lag changes dynamically with time, glucose levels, and across individuals — making in vivo interstitial glucose sampling inherently imprecise and algorithmically indistinguishable from drift in naive implementations. According to research from the University of Virginia, a unified noise estimation and short-horizon prediction framework — with a prediction horizon below 20 minutes — is required to separate physiological lag from genuine sensor degradation.
End-of-life drift represents the most extreme form of sensitivity loss. Algorithms must compute a “downward drift” metric — the error at calibration — which is normalised for irregular calibration timing and smoothed via moving average or exponential smoothing to quantify end-of-life symptoms and generate a risk factor metric value. This systematic tracking of drift magnitude therefore serves both as a correction input and as a sensor termination criterion.
PISA is a physically distinct artifact class in which mechanical pressure on the CGM sensor — during sleep or physical activity — compresses the tissue at the insertion site and attenuates the electrochemical signal. PISA can be misidentified as true glucose hypoglycaemia or as chemical drift, and requires its own dedicated detection and correction logic separate from enzymatic drift algorithms.
Factory-embedded drift profiles: correcting CGM sensor drift before implantation
Factory calibration is the most upstream correction strategy available: it encodes the individual sensor’s predicted drift behaviour into an algorithm before the device is ever implanted, eliminating the need for patient-side fingerstick calibration. Zense-Life Inc. pioneered this approach in patents filed in 2024 across US and WO jurisdictions, disclosing a method in which a processor automatically generates a correlation between enzyme membrane thickness, glucose-limiting membrane thickness, and working wire diameter — all measured during manufacturing — and at least one of a factory sensitivity value or a drift profile.
Factory calibration of CGM sensors, as patented by Zense-Life Inc. (US, 2024), correlates enzyme membrane thickness, glucose-limiting membrane thickness, and working wire diameter measured during manufacturing with a pre-assigned drift profile, enabling the sensor to output glucose readings based on that profile during in-vivo use without requiring patient fingerstick calibration.
Multiple drift profiles can be embedded in a cloud-based algorithm platform. Based on manufacturing data — enzyme membrane thickness and initial sensitivity measurements — specific profiles are assigned to individual sensors to optimise long-term performance. The Zense-Life WO filing adds that the greater the initial sensor slope (sensitivity), the more predictable and correctable the long-term drift behaviour. This is consistent with the broader industry trajectory toward factory-calibrated, calibration-free CGM sensors.
“The greater the initial sensor slope (sensitivity), the more predictable — and correctable — the long-term drift behaviour.” — Zense-Life Inc., WO, 2024
A complementary approach from Chongqing Lianxin Zhikang Biotech (CN, 2026) uses factory-verified sensitivity as a core input parameter for a nonlinear compensation model. By explicitly encoding each sensor’s initial response characteristics into the blood glucose estimation model, the approach eliminates the root cause of inter-sensor variability arising from differences in enzyme activity and production process — reducing the need for repeated manual calibration throughout the sensor’s operational life. This two-pronged strategy — pre-assigned drift profiles combined with nonlinear compensation — reflects the emerging consensus that manufacturing variability must be addressed at the source, not compensated for retrospectively.
Explore the full CGM sensor drift patent landscape with PatSnap Eureka’s AI-powered search.
Analyse CGM Patents in PatSnap Eureka →Time-dependent compensation functions, noise estimation, and signal-only calibration
Time-dependent compensation functions applied to raw sensor output during wear are the most broadly deployed class of drift correction in the CGM patent literature. Dexcom’s core approach, described in its 2016 US filing, converts raw sensor data to analyte sensor data using a conversion function, then applies a drift compensation function to compensate for changes in sensor responsiveness over time. The same patent addresses a critical corner case: reused sensors have a different sensitivity profile than new ones, and if the system incorrectly assumes all initialised sensors are new, it may apply wrong calibration assumptions, producing artificially inflated or deflated glucose readings.
For analogue, signal-level correction without any reference fingerstick, Dexcom’s transcutaneous analyte sensor patent family (AU, 2024) provides a self-calibration approach based on the sensor signal alone. The technique applies forward and backward filters to the sensor signal, optimising seed parameters to minimise mean squared error between the two filters. The calibration then adjusts sensor sensitivity and baseline according to two criteria: consistency of mean glucose with expected diabetic population means, and consistency of glucose variability with the measured mean glucose level. This signal-only approach is strategically important as it enables fully factory-calibrated, no-fingerstick CGM systems — a key regulatory and usability milestone tracked by organisations such as the FDA.
Tandem Diabetes Care (US, 2016) introduced a forward-looking variant: a predictive calibration system that generates calibration curves from at least two measured data values and determines a transformation function that extrapolates to produce a predictive calibration curve. Rather than only correcting for past drift, the system anticipates how the calibration curve will evolve and uses the predicted curve to estimate current glucose values — reducing the lag between actual drift and algorithmic compensation.
Ascensia Diabetes Care Holdings AG (TW, 2026) takes a different signal-processing approach, applying probe potential modulation sequences to the sensor alongside a constant voltage potential. The resulting primary current signal and probe modulation current signal are used together through a “connection function” to derive a final glucose concentration, enabling real-time, model-driven compensation of both sensitivity drift and baseline shift within a single measurement cycle.
The University of Virginia’s accuracy framework (US, 2008), published in work also cited by WIPO-registered filings, calibrates the CGS dynamically by scheduling recalibration based on the monitored CGS value and its rate of change (first derivative). Recalibration is triggered or deferred based on whether the absolute value of the first time derivative falls below a threshold — effectively performing calibration only when the glucose signal is quasi-stationary and the blood-to-interstitial gradient is minimised.
Dexcom’s time-dependent drift compensation approach (US, 2016) applies a drift compensation function to raw CGM sensor output to compensate for changes in sensor responsiveness over time, and also detects whether a sensor is newly implanted or being reused from a previous session — because reused sensors have a different sensitivity profile that requires different calibration assumptions.
Machine learning, artifact detection, and orthogonal sensor fusion for drift correction
Machine learning models have been applied to classify drift-related artifacts and separate them from true physiological glucose changes, using multi-dimensional input signals that single-channel analysis cannot resolve. Medtronic MiniMed’s EP patent (2022) describes ML models trained to classify CGM sensor data and blank data points flagged as outliers. The system uses interstitial current signal (Isig), electrochemical impedance spectroscopy (EIS), and counter voltage (Vcntr) as simultaneous inputs — rather than univariate signal analysis — enabling far more reliable classification of sensor error conditions including drift. Sensors with an excessive accumulation of blanked data may be terminated algorithmically. EIS is particularly informative because it provides chemical information about the sensor membrane state beyond what can be inferred from glucose current alone.
Two-stage PISA detection pipeline
The University of Virginia Patent Foundation has developed a multi-model machine learning architecture specifically for pressure-induced sensor attenuation (PISA). A first ML model identifies candidate glucose time series containing compression artifacts; a second ML model confirms whether those measurements were taken while the sensor was actually subject to compression — providing a two-stage artifact classification pipeline. A companion system uses a clearance value computed between baseline blood glucose measurements and current blood glucose measurements, flagging compression when the clearance value exceeds a predefined threshold in real time.
Chongqing Lianxin Zhikang Biotech (CN, 2026) addresses nocturnal non-physiological signal depressions using a dual-dimension discrimination logic: time-domain feature extraction first classifies whether a signal segment constitutes a short-term depression, then physiological-dimension rules verify whether it corresponds to true hypoglycaemia. Non-physiological depressions are corrected via a linear extrapolation algorithm applied to the pre-depression baseline, restoring an accurate signal without inadvertently masking genuine hypoglycaemic events.
Medtronic MiniMed has patented a hardware-plus-algorithm strategy combining optical and electrochemical measurement modalities in parallel. Integrity checks are performed on sensor glucose values from both modalities — checking for sensitivity loss, noise, and drift — before calibration is applied. The two sensor glucose values are then weighted by their respective reliability index (RI) and fused into a single combined output, providing intrinsic self-consistency validation that single-sensor architectures cannot achieve.
Shenzhen Kefu Biotech (CN, 2024) applies deep learning to supervised training on sensor decay data segmented by attenuation characteristics. The system uses piecewise fitting via least squares to model the initial glucose concentration dataset during the attenuation period, then applies data mining constraints on individual sensors to prevent over-calibration — which can introduce errors larger than the drift itself. This two-layer approach, combining population-level model training with individual sensor constraints, reflects the emerging consensus that purely global correction models are insufficient for manufacturing-variable sensors. Standards bodies including ISO have set accuracy requirements for CGM devices that make such per-sensor constraints clinically necessary.
Map the full ML-in-CGM patent landscape with PatSnap Eureka’s AI-powered innovation intelligence.
Explore Patent Data in PatSnap Eureka →Dexcom’s adaptive CGM system (JP, 2024) incorporates accelerometer-derived orientation data to identify the physical location of the sensor insertion site and corrects glucose values based on that location — addressing the underappreciated problem that insertion site physiology (abdominal vs. arm placement) systematically influences sensor output and drift characteristics. This insertion-site-aware correction represents a further dimension of personalisation beyond population-level drift models.
Medtronic MiniMed’s orthogonally redundant sensor architecture (CA, 2015) combines optical and electrochemical CGM modalities in parallel, performing integrity checks for sensitivity loss, noise, and drift on both sensor types before weighting each by its reliability index (RI) and fusing the outputs into a single combined glucose value — providing self-consistency validation that single-modality CGM systems cannot replicate.
Patent landscape: who is building the CGM drift correction stack
Dexcom, Inc. is the dominant patent holder in this dataset, with 12 or more entries spanning time-dependent drift compensation, self-calibration using signal-only algorithms, retrospective retrofitting, and adaptive sensor systems. The company’s trajectory reflects a strategy of eliminating user-facing calibration by embedding sophisticated drift correction into the factory and sensor electronics — a direction that aligns with broader industry and regulatory pressure toward no-fingerstick CGM devices. The PatSnap IP Intelligence platform provides full family analysis of Dexcom’s continuation filing strategy across these correction methods.
The University of Virginia Patent Foundation is the most prolific academic contributor, with 10 or more entries covering noise estimation for accuracy improvement, PISA detection, data compression, and HbA1c modelling from CGM data. Its PISA detection work — filed across US, WO, AU, JP, and CN — represents the most comprehensive algorithmic treatment of physical artifact-driven drift in the dataset. Medtronic MiniMed has patented redundant sensor architectures with cross-modality drift detection, alongside ML-based outlier classification systems incorporating EIS — an approach that provides chemical information about the sensor membrane state beyond what can be inferred from glucose current alone.
Ascensia Diabetes Care Holdings AG has filed across US, WO, and TW for gain-function-based real-time compensation approaches that use historical signal windows to compute compensated glucose values, with a strong emphasis on error detection during continuous sensing. Zense-Life Inc. has carved a specific niche in factory calibration and pre-assigned drift profiles across US, WO, and CN — an approach that aligns with the industry trajectory toward zero-calibration devices.
Chongqing Lianxin Zhikang Biotech and Shenzhen Kefu Biotech represent an emerging cluster of Chinese innovators applying nonlinear compensation models, deep learning, and adaptive calibration to address both inter-sensor manufacturing variability and intra-individual physiological drift. Their 2024–2026 filings signal that the next wave of CGM drift correction innovation will be driven partly by Asian medical device manufacturers, a trend consistent with the broader global diffusion of diabetes technology noted by the World Health Organization. Full analysis of these emerging assignees is available through the PatSnap Analytics suite.
“Retrospective retrofitting algorithms that combine sparse blood glucose reference measurements with time-series CGM data and explicit drift models can reconstruct accurate glucose profiles even from heavily drifted data.”
The retrospective retrofitting approach — originally developed at the University of Padova (WO, 2014) and subsequently filed under Dexcom — simultaneously exploits the high accuracy of sparse blood glucose reference measurements and the high temporal resolution of noisy CGM data. A model of blood-to-interstitial glucose kinetics and a model of the time-dependent deterioration of sensor accuracy are combined via an optimisation algorithm to produce a quasi-continuous, drift-corrected blood glucose profile. This approach is especially valuable in clinical trial settings where only sparse reference measurements are available to anchor the correction.